OIG Advisory Opinion: 14-05

    Favorable

    Pharmacy vendor fees for dispensing services in a direct-to-patient drug sales program

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    OIG said vendor service fees can be okay if they're fair market value, set in advance, based on independent valuation, and not tied to referrals or volume.

    ✓A pharmaceutical manufacturer contracted with an online pharmacy to dispense a brand-name drug directly to patients for a fixed cash price, outside of insurance. The manufacturer paid the pharmacy flat monthly fees plus per-transaction fees for dispensing, storage, enrollment, and patient communication services.

    ✓OIG acknowledged these payments are remuneration, which means they could trigger Anti-Kickback concerns if the pharmacy could arrange for or recommend purchases of the manufacturer's other federally reimbursable products.

    ✓OIG concluded favorably because the fees were arrived at through arm's-length negotiations, were consistent with fair market value, were based on independent third-party valuation, and did not take into account the value or volume of referrals or other business generated between the parties.

    ✓The per-transaction fees covered only services necessary to dispense the product, not marketing or other non- integral services, and the arrangement prohibited both parties from marketing other products or services to participants, which reduced inducement risk.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Have independent third-party FMV documentation for all vendor fees, whether flat fees, per-transaction fees, or monthly fees, covering every service category (dispensing, storage, enrollment, communication, IT development, etc.).

    ✓Prove fees were established through arm's-length negotiations and are not tied to referral volume, collections, or business generated between the parties.

    ✓Show that per-transaction or variable fees cover only services actually necessary to deliver the product or service, not marketing, promotional activities, or inducements to steer business.

    ✓Keep a written service agreement that defines scope, prohibits the vendor from offering inducements to refer other products, and includes audit rights to confirm compliance.

    ✓Document that fee amounts are consistent with what the vendor would charge unrelated third parties for comparable services in arm's-length transactions.

    If your vendor compensation structure can't demonstrate arm's-length FMV support and independence from referral volume, you're at risk of it reading like payment for steering.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    FAVORABLE

    OIG WATCH 14-05

    Pharmacy vendor fees for dispensing services in a direct-to-patient drug sales program

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals